Brought to you by 
Mundipharma gets European rights to SkyePharma's DepoCyte
17 Aug 2011
Executive Summary
Mundipharma (drug delivery) has licensed exclusive marketing and distribution rights (covering most of Europe and all of Eastern Europe) to SkyePharma's DepoCyte (cytarabine), a therapeutic for lymphomatous meningitis, a complication from cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mundipharma gets European rights to SkyePharma's DepoCyte
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice